BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 752874)

  • 1. Adjuvant therapy in malignant melanoma: a trial of immunotherapy. chemotherapy, and combined treatment.
    Kaufman SD; Cosimi AB; Wood WC; Carey RW
    Recent Results Cancer Res; 1978; 68():380-6. PubMed ID: 752874
    [No Abstract]   [Full Text] [Related]  

  • 2. Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.
    Veronesi U; Beretta G
    Recent Results Cancer Res; 1978; 68():375-9. PubMed ID: 752873
    [No Abstract]   [Full Text] [Related]  

  • 3. Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
    Peter HH; Deutschmann KE; Deinhardt J; Deicher H
    Recent Results Cancer Res; 1978; 68():367-74. PubMed ID: 752872
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: Chemoimmunotherapy of malignant melanoma.
    N Engl J Med; 1975 Jan; 292(3):159-60. PubMed ID: 1196343
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.
    Hedley DW; McElwain TJ; Currie GA
    Eur J Cancer (1965); 1977 Oct; 13(10):1169-73. PubMed ID: 923614
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Wood WC; Cosimi AB; Carey RW; Kaufman SD
    Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
    Newlands ES; Oon CJ; Roberts JT; Elliott P; Mould RF; Topham C; Madden FJ; Newton KA; Westbury G
    Br J Cancer; 1976 Aug; 34(2):174-9. PubMed ID: 962994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
    El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
    Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacillus Calmette-GuĂ©rin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
    Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
    Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
    Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
    Green MD; MacKay IR; Buckley JC; Coates AS
    Aust N Z J Surg; 1979 Jun; 49(3):335-9. PubMed ID: 289374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant immunotherapy of malignant melanoma.
    Aranha GV; McKhann CF; Grage TB; Gunnarsson A; Simmons RL
    Cancer; 1979 Apr; 43(4):1297-303. PubMed ID: 445331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
    Mitchell MS; Mokyr MB; Davis JM
    J Clin Invest; 1977 Jun; 59(6):1017-26. PubMed ID: 863999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [DTIC in malignant melanoma: a perspective (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
    Pullmann H; Muth M
    Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
    [No Abstract]   [Full Text] [Related]  

  • 17. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
    Agarwala SS; Neuberg D; Park Y; Kirkwood JM
    Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letter: Treatment of malignant melanoma.
    Constanza ME; Nathanson L
    Lancet; 1974 Dec; 2(7896):1565. PubMed ID: 4140995
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial: Treatment of malignant melanoma.
    Lancet; 1974 Nov; 2(7889):1119-20. PubMed ID: 4139412
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
    Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
    N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.